Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No	Ailment	Route	Dose Min	Dose Max	Unit	Dosage Form	Frequency	Additional Info
1	Male hypogonadal disorders	IM	50	400	mg	Injection		Dose: Testosterone cipionate: given every 2 to 4 weeks
2	Male hypogonadal disorders	IM	50	400	mg	Injection		Dose: testosterone enantate: every 2 to 4 weeks, or an initial dose of 250 mg every 2 to 3 weeks followed by maintenance dosing every 3 to 6 weeks
3	Male hypogonadal disorders	IM		50	mg	Injection		Dose: Testosterone propionate: given two or three times weekly
4	Male hypogonadal disorders	IM	1		gm	Injection		Dose: Testosterone undecylate: every 10 to 14 weeks
5	Adjunct to menopausal HRT for symptoms such as decreased libido		50	100	mg	Implant		Dose: Given every 4 to 8 months
6	Menopausal vasomotor symptoms	IM				Injection		Dose: Testosterone cipionate 50 mg with estradiol cipionate 2 mg have been given once every 4 weeks, with attempts to taper treatment at 3 to 6 month intervals
7	Hypoactive sexual desire disorder in women with surgically induced menopause (bilateral oophorectomy and hysterectomy) who are receiving oestrogen therapy	Transdermal	300		micrograms	Transdermal Patch		The patch is applied twice weekly, the initial response to therapy should be evaluated after 3 to 6 months and reassessed every 6 months.
8	Hormonal therapy of disseminated breast carcinoma	IM	200	400	mg	Injection		Dose: given every 2 to 4 weeks

Adult Dose

S.No	Ailment	Route	Dose Min	Dose Max	Unit	Dosage Form	Frequency	Additional Info
1	Male hypogonadal disorders	IM	50	400	mg	Injection		Dose: Testosterone cipionate: given every 2 to 4 weeks
2	Male hypogonadal disorders	IM	50	400	mg	Injection		Dose: testosterone enantate: every 2 to 4 weeks, or an initial dose of 250 mg every 2 to 3 weeks followed by maintenance dosing every 3 to 6 weeks
3	Male hypogonadal disorders	IM		50	mg	Injection		Dose: Testosterone propionate: given two or three times weekly
4	Male hypogonadal disorders	IM	1		gm	Injection		Dose: Testosterone undecylate: every 10 to 14 weeks
5	Adjunct to menopausal HRT for symptoms such as decreased libido		50	100	mg	Implant		Dose: Given every 4 to 8 months
6	Menopausal vasomotor symptoms	IM				Injection		Dose: Testosterone cipionate 50 mg with estradiol cipionate 2 mg have been given once every 4 weeks, with attempts to taper treatment at 3 to 6 month intervals
7	Hypoactive sexual desire disorder in women with surgically induced menopause (bilateral oophorectomy and hysterectomy) who are receiving oestrogen therapy	Transdermal	300		micrograms	Transdermal Patch		The patch is applied twice weekly, the initial response to therapy should be evaluated after 3 to 6 months and reassessed every 6 months.
8	Hormonal therapy of disseminated breast carcinoma	IM	200	400	mg	Injection		Dose: given every 2 to 4 weeks

Ref :-  Book : Martindale    Page : 2340   Edition : 37  

Pediatric Dose

Ref :- Book : Martindale    Page : 2340   Edition : 37  

►  Side Effect : Increased retention of sodium and water, oedema, hypercalcaemia, and impaired glucose tolerance., Increased lowdensity- lipoprotein cholesterol, decreased high-density- lipoprotein cholesterol, increased haematocrit, and suppression of clotting factors., Headache, Depression, Gastrointestinal bleeding, Jaundice, Cholestatic hepatitis, Peliosis hepatis and hepatic tumours in patients who have received high doses over prolonged periods., In men, large doses suppress spermatogenesis and cause testicular atrophy. Epididymitis and bladder irritability can occur. Priapism is a sign of excessive dosage and may occur especially in elderly males, Gynaecomastia may occur. Androgens may cause prostatic hyperplasia and accelerate the growth of malignant neoplasms of the prostate, In women, the inhibitory action of androgens on the activity of the anterior pituitary results in the suppression of ovarian activity and menstruation. Continued use produces symptoms of virilism, such as hirsutism or male-pattern baldness, deepening of the voice, atrophy of the breasts and endometrial tissue, oily skin, acne, and hypertrophy of the clitoris., Virilisation may not be reversible, even after stopping therapy.
Ref :-   Book : Martindale    Page : 2338   Edition : 37.  
►  Drug Interaction : Drug interaction of Testosterone is with ,  Levothyroxine, Warfarin
Ref :-   Book : Martindale    Page : 2339   Edition : 37.  

Drug interaction

Drug Interaction : Drug interaction of Testosterone is with ,  Levothyroxine, Warfarin

Book : Martindale    Page : 2339   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Testosterone and other androgens and anabolic steroids have been reported to enhance the activity of a number of drugs, with resulting increases in toxicity. Drugs affected include ciclosporin, levothyroxine, and anticoagulants such as warfarin. Resistance to the effects of neuromuscular blockers has also been reported. As androgens and anabolic steroids can alter glucose metabolism, doses of insulin or oral antidiabetics may need adjustment.
Ref :-   Book : Martindale    Page : 2339   Edition : 37.  

Mechanism of Drug

Mechanism of Drug Drug Interaction : Testosterone and other androgens and anabolic steroids have been reported to enhance the activity of a number of drugs, with resulting increases in toxicity. Drugs affected include ciclosporin, levothyroxine, and anticoagulants such as warfarin. Resistance to the effects of neuromuscular blockers has also been reported. As androgens and anabolic steroids can alter glucose metabolism, doses of insulin or oral antidiabetics may need adjustment.

Book : Martindale    Page : 2339   Edition : 37.  

►  Contraindication : Testosterone and other androgens and anabolic steroids should be used cautiously in patients with cardiovascular disorders, renal or hepatic impairment, epilepsy, migraine, diabetes mellitus or other conditions that may be aggravated by the possible fluid retention or oedema caused., They should not be given to patients with hypercalcaemia or hypercalciuria, and should be used cautiously in conditions in which there is a risk of these developing such as skeletal metastases., The use of the 17α-alkylated derivatives, which are associated with an increased risk of hepatotoxicity, is probably best avoided in patients with hepatic impairment, and certainly if this is severe. Hepatic function should be monitored during therapy., In men, androgens and anabolic steroids should not be given to those with carcinoma of the breast or prostate (although in women they have been used in the treatment of certain breast carcinomas., The prostate should be examined regularly during treatment., Androgens and anabolic steroids should be used with extreme care in children because of the masculinising effects and also because premature closure of the epiphyses may occur resulting in inhibited linear growth and small stature. Skeletal maturation should be monitored during therapy., Patients using testosterone gels should take care to wash their hands after every application, and to cover the site with clothing once the gel has dried. The area should also be washed thoroughly before skin-to-skin contact with another person. Inappropriate virilisation, advanced bone age, increased libido, and aggressive behavior have been reported in children who have been reported in children who have been inadvertently exposed to testosterone in this way
Ref :-   Book : Martindale    Page : 2339   Edition : 37.  

  ►  Mechanism of Action :   Testosterone can act as an androgen either directly, by binding to the androgen receptor, or indirectly by conversion to dihydrotestosterone, which also binds to the androgen receptor. Testosterone and dihydrotestosterone act as androgens via a single androgen receptor . The androgen receptor—officially designated NR3A—is a member of the nuclear receptor superfamily. In the absence of a ligand, the androgen receptor is located in the cytoplasm associated with a heat-shock protein complex. When testosterone or dihydrotestosterone binds to the ligand-binding domain, the androgen receptor dissociates from the heat-shock protein complex, dimerizes, and translocates to the nucleus. The dimer then binds via the DNA-binding domains to androgen response elements on certain responsive genes. The ligand-receptor complex recruits coactivators and acts as a transcription factor complex, stimulating or repressing expression of those genes.
Ref :-   Book : Goodman    Page : 1197   Edition : 12.  

►   Route of Elimination :   Hepatic (Metabolism), Renal, Faecal
Ref :-   Book : Martindale    Page : 2339   Edition : 37.  
►    Plasma Half-life :   Min value :-   10 minutes,    Max value :-   100 minutes.  
Ref :-   Book : Martindale    Page : 2339   Edition : 37.  
►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA